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Volume 54, Number 6 Letters to the Editor 1869basis of their underlying malignancy. Unfortunately, our study
does not provide definitive answers to the above-mentioned ques-
tions, but confirms that survival was low in the overall cohort, and
that CAS was performed with low peri-procedural risk but with
high restenoses rates. We continue to indicate carotid revascular-
ization after a careful discussion of our institutional results, the
risks of stroke or stroke-related disability, the patients overall
prognosis, and the anatomical characteristics of the lesion. In
general, patients with no evidence of recurrent cancer and who are
symptomatic and have suitable anatomy are treated by either CAS
or open surgery, depending on factors such as presence of concom-
itant radical neck dissection, tracheostomy, or skin damage. For
asymptomatic patients, we recognize that the indication of revas-
cularization remains controversial and that one should carefully
analyze the patient’s life expectancy and anatomical risk for the
procedure. However, carotid revascularization continues to have a
role in selective patients with significant progression of the carotid
lesion and no evidence of recurrentmetastatic disease or limited life
expectancy.
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Regarding “Evaluation of the Endurant stent graft
under instructions for use vs off label conditions for
endovascular aortic aneurysm repair”
We read the article by Torsello et al with interest.1 While the
use of endovascular aneurysm repair (EVAR) has revolutionized
the management of infrarenal abdominal aortic aneurysm (AAA)
its use has only been shown feasible in 40% to 60% of AAA.
Advances in technology, imaging, graft design, and operator expe-
rience has lead to an extension of their use beyond initial manufac-
turer’s guidelines. The device studied in this article is licensed to a
10-mm neck extending or rather shortening the previous bench-
mark of 15 mm. Nevertheless, the ability to place the graft at
operation outside this use is shown to be associated with increased
type I endoleak. Numbers did not reach significance as the primary
endpoint frequency was low and study group small.
We have previously shown that use of EVAR outside IFU was
associated with a worse outcome that translated into patient mor-
tality in symptomatic AAA.2 Recently we conducted a review of the
EUROSTAR database of over 75003 cases to determine the long-
term outcome of elective infrarenal endografts inserted outside the
manufacturers’ IFUs. We found a significant association between
a
ehe “off label” use of endografts and the incidence of type 1
ndoleak, which is in agreement with the authors. However, our
ata also showed that grafts placed outside IFU were associated
ith increased all-cause mortality and type I endoleak was
ssociated with increased aneurysm related mortality at long-
erm follow-up. The grafts in our study, however, were older
eneration and did not include the Endurant. These datasets
upport the authors comments that use of EVAR outside IFU
an be done but short-term results that may appear satisfactory
re in fact significantly worse in long-term follow-up.
We suggest that use of devices outside license or recom-
ended usage should be undertaken only in the centers with
obust data collection, or better still, in clinical trials. EVAR is an
xcellent prophylactic treatment for infrarenal AAA when under-
aken correctly, however, it appears less effective if outside IFU and
ncreases the risk for long-term failure. Long-term follow-up of
VAR has shown the early advantages of infrarenal EVARs over
pen surgery disappear with time.4 The consequence of using
off-label” stent grafts may have resulted in steadily increased
umbers of ruptured aneurysms. This has prompted us to resort to
more liberal use of fenestrated stent grafts, given the excellent
arly results with the latter.
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We read with interest the comment of Cross et al and we thank
hem for the attention paid to our article.
We completely agree with the authors that the use of en-
ografts outside the manufacturers’ instructions for use (IFU) was
esponsible of a higher risk of type I endoleak1; our population
tudy did not have the right power to obtain a statistical signifi-
ance, but we explained this bias in the text. Furthermore, our
ollow-up was too short to give rough conclusions.2
Then, we agree with the authors that the applicability of endo-
ascular aneurysm repair outside IFU should be reserved for those
enters with great experience in aortic endovascular procedures.
In other reports, we suggested the use of alternative procedures
fenestrated stent grafts, chimney technique) in selected patients with
long life expectancy and with stable lesions, even if these advanced
ndovascular techniques have still not resolved problems. In fact, the
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treated with fenestrated stent grafts is not negligible,3 and the chim-
ney technique shows satisfying results in series with a small number of
patients with a short-term follow-up.4
The Endurant stent graft is a new-generation device and we
are expecting better long-term results in terms of migration, mod-
ule disconnection, and fatigue of the materials than those offered
by the first- and second-generation devices.5 So, we confirm the
cautious application in selected patients of endovascular aneurysm
repair outside the Endurant-specific IFU.2
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Carotid artery stenting may be contraindicated in
female patients with symptomatic carotid artery
stenosis
Carotid artery stenting (CAS) has reported inferior outcomes
compared with carotid endarterectomy (CEA) for the manage-
ment of symptomatic carotid artery stenosis.1 The 2011 guidelines
by the American Heart Association/American Stroke Association
(AHA/ASA) and several other associations recommended CAS as
an “alternative to CEA for symptomatic patients” (class I; level of
evidence B).2 The AHA/ASA Guidelines used the Carotid Revas-
cularization Endarterectomy versus Stenting Trial (CREST) to
support this recommendation.3
CREST recently reported a subgroup analysis on the influ-
ence of sex on outcomes after CAS compared with CEA.4
Although symptomatic men showed similar periprocedural
stroke rates whether undergoing CAS or CEA (3.3% vs 2.4%,
respectively; hazard ratio [HR], 1.39; 95% confidence interval
[CI], 0.78-2.48; P  .26), women assigned to CAS had 2.5-
fold higher periprocedural stroke rates compared with those
undergoing CEA (5.5% vs 2.2%, respectively; HR, 2.63; 95%
CI, 1.23-5.65; P  .013). Similar results were reported for
periprocedural death rates. As the authors commented,
4women might be at higher risk of periprocedural stroke and
eath because of technical difficulties related to the fact that
hey have smaller internal carotid arteries than men; women,
n average, have 40% smaller internal carotid arteries than
en.”4
Another recent report compared the outcomes of CAS vs CEA
n women vs men using the Nationwide Inpatient Sample (n 
4,658 procedures) during 2004 and 2005.5 Although females
ad similar rates of perioperative stroke with males undergoing
EA (1.0% vs 1.0%, respectively; P  .9) or CAS (2.7% vs 2.0%,
espectively; P  .2), symptomatic women had higher periopera-
ive stroke rates compared with either asymptomatic females (3.8%
s 0.9%, respectively; P  .001) or symptomatic men (3.8% vs
.3%, respectively; P  .03).5 The conclusion reached was that
CEA may be the preferred treatment in female patients who
arrant intervention for cerebrovascular disease, unless compelling
easons exist to perform CAS.”5
Maneuvering CAS guidewires and catheters in the smaller
emale carotid arteries with “unstable” plaques may produce more
icroemboli than inmales; these microemboli may account for the
ncreased periprocedural stroke rates in symptomatic female pa-
ients undergoing CAS.4,5
The inferior results of CAS compared with CEA for symp-
omatic female patients,4,5 therefore, indicate that CAS is not an
cceptable “alternative” to CEA in this group of patients.
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